移动卒中单元与医院环境下超早期静脉溶栓治疗急性缺血性卒中的比较
本研究比较移动卒中单元(MSU)与医院环境(HS)下超早期(发病后第一个黄金小时内)静脉溶栓的急性缺血性卒中患者的特征与结局。MSU-GH组117例,HS-GH组136例,两组3个月良好功能结局率(51.3% vs 46.2%,P=0.487)和死亡率(7.7% vs 9.9%,P=0.576)均无显著差异,校正混杂因素后MSU治疗与良好功能结局(OR 1.84,95%CI 0.86-3.96)或死亡率(OR 0.95,95%CI 0.28-3.20)也无显著关联。结论认为无证据表明超早期静脉溶栓的安全性和有效性在MSU与HS中存在差异。
要点
- MSU-GH组3个月良好功能结局率为51.3%,HS-GH组为46.2%,两组无显著差异(P=0.487)。
- MSU-GH组3个月死亡率为7.7%,HS-GH组为9.9%,两组无显著差异(P=0.576)。
- 校正混杂因素后,MSU治疗与良好功能结局(OR 1.84,95%CI 0.86-3.96)和死亡率(OR 0.95,95%CI 0.28-3.20)均无显著关联。
核心结论
- 无证据表明超早期静脉溶栓治疗急性缺血性卒中的安全性和有效性在移动卒中单元与医院环境中存在差异。
研究设计与样本
- MSU-GH患者选自柏林STEMO(移动卒中单元),HS-GH患者选自SITS-EAST注册研究。
- 共纳入117例MSU-GH患者(占305例MSU治疗患者的38.4%)和136例HS-GH患者(占15591例HS治疗患者的0.9%),均无卒中前残疾。
- 比较两组3个月良好功能结局(改良Rankin量表评分0或1)、改良Rankin量表评分分布及死亡率。
主要发现
- 3个月良好功能结局率:MSU-GH组51.3% vs HS-GH组46.2%,P=0.487,无显著差异。
- 3个月死亡率:MSU-GH组7.7% vs HS-GH组9.9%,P=0.576,无显著差异。
- 3个月改良Rankin量表评分分布两组比较P=0.196,无显著差异。
- 多因素logistic回归校正潜在混杂因素后,MSU治疗与良好功能结局无显著关联(OR 1.84,95%CI 0.86-3.96)。
- 多因素logistic回归校正潜在混杂因素后,MSU治疗与死亡率无显著关联(OR 0.95,95%CI 0.28-3.20)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Mobile stroke units (MSUs) are known to increase the proportion of acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT) in the first golden hour (GH) after onset compared with hospital settings (HS). However, because of the low number of AIS patients treated with intravenous thrombolysis within this ultraearly time window in conventional care, characteristics, and outcome of this subgroup of AIS patients have not been compared between MSU and HS. Methods- MSU-GH patients were selected from the Berlin-based MSU (STEMO [Stroke Emergency Mobile]), whereas HS-GH patients were selected from the SITS-EAST (Safe Implementation of Treatments in Stroke-East) registry. The outcome events of interest included the rates of favorable functional outcome (modified Rankin Scale scores of 0 or 1), distribution of the modified Rankin Scale scores, and mortality after 3 months between MSU-GH and HS-GH groups. Results- We identified 117 MSU-GH (38.4% of 305 MSU-treated patients) and 136 HS-GH (0.9% of 15 591 HS-treated patients) eligible patients without prestroke disability. No significant differences were documented in the rates of favorable functional outcome (51.3% versus 46.2%, P=0.487) and mortality (7.7% versus 9.9%, P=0.576) at 3 months, or in the distribution of 3-month modified Rankin Scale scores between the 2 groups ( P=0.196). In multivariable logistic regression analyses, adjusting for potential confounders, MSU treatment was not associated with a significantly different likelihood of favorable functional outcome (odds ratio, 1.84 for MSU patients; 95% CI, 0.86-3.96) or mortality (odds ratio, 0.95; 95% CI, 0.28-3.20) at 3 months. Conclusions- There is no evidence that safety and efficacy of ultraearly intravenous thrombolysis for AIS differs when used in MSUs or in HS.
引用
- Tsivgoulis G, Geisler F, Katsanos AH, et al. Ultraearly Intravenous Thrombolysis for Acute Ischemic Stroke in Mobile Stroke Unit and Hospital Settings. Stroke. 2018. PMID: 29986934. doi:10.1161/STROKEAHA.118.021536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。